Classification of hypertension

Reading File

Finding Sources

Searching PubMed

"hypertension" AND "classification" AND "guidelines"

Reading File

Searching Images

hypertension blood pressure classification table JNC ACC AHA ESH

Table 5. Summary of Clinical Treatment Guidelines for Hypertension Treatment <table><thead><tr><th>Guidelines</th><th>Definition</th><th>Target blood pressure</th><th>First-line agents</th><th>Indication for dual antihypertensive therapy</th></tr></thead><tbody><tr><td>ACC/AHA</td><td>130/80</td><td><130/80</td><td>Diuretics<br>Angiotensin-converting enzyme inhibitors*<br>Angiotensin receptor blockers*<br>Calcium channel blockers</td><td>>140/90</td></tr><tr><td>ADA</td><td>140/90</td><td><140/90 Or <130/80 with high cardiovascular risk (existing atherosclerotic cardiovascular disease or 10-y risk score ≥15%) provided it can be safely attained</td><td>Angiotensin-converting enzyme inhibitors*<br>Angiotensin receptor blockers *<br>Thiazide-like diuretics<br>Dihydropyridine calcium channel blockers</td><td>>160/100</td></tr></tbody></table> *Preferred agents with albuminuria.

Table 11. Related Guideline Content <table><thead><tr><th>Recommendation Number</th><th>Guideline Title</th><th>Organization</th><th>Publication Year</th></tr></thead><tbody><tr><td>1.2, 3.1</td><td>Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Journal of the American College of Cardiology 2014;63:2935–2959</td><td>ACC/AHA</td><td>2014</td></tr><tr><td>1.4</td><td>American Diabetes Association Standards of Medical Care in Diabetes 2019 Diabetes Care 2019 Jan;42(Suppl 1)</td><td>ADA</td><td>2019</td></tr><tr><td>1.5, 1.6, 3.8</td><td>Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Hypertension 2018;71:1269–1324</td><td>ACC/AHA/AAPA/ ABC/ACPM/AGS/ APhA/ASH/ASPC/ NMA/PCNA</td><td>2017</td></tr><tr><td>2.3</td><td>Health and Human Services Office of Disease Prevention and Health Promotion and US Department of Agriculture Center for Nutrition Policy Promotion 2015-2020 Dietary Guidelines for Americans, 8th ed. https://health.gov/dietaryguidelines/2015/guidelines</td><td>HHS/USDA</td><td>2015</td></tr><tr><td>2.4</td><td>2018 Physical Activity Guidelines Advisory Committee 2018 Physical Activity Guidelines Advisory Committee Scientific Report Washington, DC: US Department of Health and Human Services; 2018</td><td>HHS</td><td>2018</td></tr><tr><td>2.4</td><td>Qaseem A, Holty JE, Owens DK, Dallas P, Starkey M, Shekelle P Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians Annals of Internal Medicine 2013;159(7):471-483</td><td>ACP</td><td>2013</td></tr><tr><td>3.1, 3.3 - 3.4, 3.6</td><td>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Journal of the American College of Cardiology 2014;63:2889–2934</td><td>ACC/AHA</td><td>2014</td></tr><tr><td>3.2</td><td>Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations Canadian Journal of Cardiology 2009;25:567–579</td><td>CCS</td><td>2009</td></tr><tr><td>3.3 - 3.4</td><td>Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL 2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Atherosclerosis 2016;253:281–344</td><td>ESC/EAS</td><td>2016</td></tr></tbody></table>

Summary : This figure presents a clinical recommendation regarding weight loss for adults with overweight or obesity, specifically targeting blood pressure and hypertension management. table: Recommendation Overview : • Recommendation is for adults who have overweight or obesity. • Weight loss is recommended with a goal of at least 5% of body weight reduction. • The purpose is to prevent or treat elevated blood pressure (BP) and hypertension. Classification Codes : • COR (Class of Recommendation): 1 • LOE (Level of Evidence): A Reference Notes : • The recommendation is supported by references 1–9. Analysis : • The table provides a high-level, evidence-based clinical guideline emphasizing the importance of modest weight loss (≥5%) in managing or preventing high blood pressure in overweight or obese adults, with a strong recommendation (Class 1, Level A evidence).

Table 1. Hypertension CPG Focus Group Concepts <table><thead><tr><th colspan="2">Patient Focus Group Themes</th></tr></thead><tbody><tr><td>A.</td><td>Provide comprehensive information and education to patients regarding their condition, management strategies, and self-management, including expanding available information on complementary and alternative therapies.</td></tr><tr><td>B.</td><td>Improve the method of measuring blood pressure in the office.</td></tr><tr><td>C.</td><td>Education around home monitoring devices and strategies for measurement and management, including frequency of measurement, is important.</td></tr><tr><td>D.</td><td>Improve communication between providers and patients, considering patient preferences regarding frequency of communication and mode of communication.</td></tr><tr><td>E.</td><td>All patients understood the importance of lifestyle modifications to lower their blood pressure.</td></tr></tbody></table>

Reading File

I now have all the key data needed. Let me compile the comprehensive answer.

Classification of Hypertension

Hypertension classification is not uniform globally - it has evolved across guidelines and can be approached in three distinct ways. Here is a full breakdown.

1. Classification by Etiology (Cause)

A. Primary (Essential) Hypertension

Accounts for 90-95% of all adult hypertension cases
No identifiable single cause
Results from a complex interplay of genetic, environmental, and hemodynamic factors

B. Secondary Hypertension

Accounts for 5-10% of cases; has an identifiable underlying cause
More common in younger patients or those with resistant hypertension

Cause	Examples
Renal parenchymal	CKD, polycystic kidney disease, glomerulonephritis
Renovascular	Renal artery stenosis (atherosclerotic or fibromuscular dysplasia)
Primary aldosteronism	Conn's syndrome, bilateral adrenal hyperplasia
Obstructive sleep apnea	Most common identifiable cause in adults
Pheochromocytoma	Catecholamine-secreting adrenal tumor
Thyroid disorders	Hypothyroidism (raised diastolic), hyperthyroidism (raised systolic)
Cushing's syndrome	Excess glucocorticoids
Coarctation of aorta	Congenital; typically presents in young patients
Drug-induced	NSAIDs, OCP, sympathomimetics, corticosteroids, calcineurin inhibitors

Comprehensive Clinical Nephrology, 7th Edition, p. 494

2. Classification by Blood Pressure Level

Multiple guideline systems exist. The three most widely used are:

A. JNC 7 Classification (USA - 2003, still widely referenced)

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal	< 120	and	< 80
Prehypertension	120-139	or	80-89
Stage 1 Hypertension	140-159	or	90-99
Stage 2 Hypertension	≥ 160	or	≥ 100

Comprehensive Clinical Nephrology, 7th Edition, p. 487

B. 2017 ACC/AHA Guidelines (USA - currently in force)

This guideline lowered the definition of hypertension from 140/90 to 130/80 mmHg, adding the category of "Elevated Blood Pressure."

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal	< 120	and	< 80
Elevated BP	120-129	and	< 80
Stage 1 Hypertension	130-139	or	80-89
Stage 2 Hypertension	≥ 140	or	≥ 90
Hypertensive Crisis	> 180	and/or	> 120

Comprehensive Clinical Nephrology, 7th Edition, p. 488

C. 2018 ESC/ESH Guidelines (European - Grades 1-3 system)

Category	Systolic (mmHg)		Diastolic (mmHg)
Optimal	< 120	and	< 80
Normal	120-129	and/or	80-84
High Normal	130-139	and/or	85-89
Grade 1 Hypertension	140-159	and/or	90-99
Grade 2 Hypertension	160-179	and/or	100-109
Grade 3 Hypertension	≥ 180	and/or	≥ 110
Isolated Systolic HTN	≥ 140	and	< 90

Diagnostic thresholds (ESC/ESH 2018):

Office BP: ≥ 140/90 mmHg
Ambulatory - Daytime: ≥ 135/85 mmHg
Ambulatory - Nighttime: ≥ 120/70 mmHg
Ambulatory - 24-hour: ≥ 130/80 mmHg
Home BP monitoring: ≥ 135/85 mmHg
Comprehensive Clinical Nephrology, 7th Edition, p. 487-488

D. 2020 International Society of Hypertension (ISH) Guidelines

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal BP	< 130	and	< 85
High-Normal BP	130-139	and/or	85-89
Grade 1 Hypertension	140-159	and/or	90-99
Grade 2 Hypertension	≥ 160	and/or	≥ 100

Office BP threshold: > 140/90 mmHg
Home BP threshold: ≥ 135/85 mmHg
Comprehensive Clinical Nephrology, 7th Edition, p. 488

3. Special Forms / Clinical Subtypes

Subtype	Definition
Isolated Systolic Hypertension	SBP ≥ 140 with DBP < 90; common in elderly due to arterial stiffness
White Coat Hypertension	Elevated office BP but normal out-of-office readings
Masked Hypertension	Normal office BP but elevated ambulatory/home BP
Resistant Hypertension	BP above target despite 3 or more antihypertensive agents (one being a diuretic) at optimal doses
Refractory Hypertension	Uncontrolled on ≥ 5 agents including a long-acting thiazide diuretic and mineralocorticoid receptor antagonist
Hypertensive Urgency	Severely elevated BP (> 180/120) without acute target organ damage
Hypertensive Emergency	Severely elevated BP with acute target organ damage (e.g., encephalopathy, AKI, dissection, pulmonary edema)

Fuster and Hurst's The Heart, 15th Edition, p. 193-194

4. Classification by Population-Based Percentile (Pediatric)

In children and adolescents, hypertension is defined statistically:

Elevated BP: SBP or DBP at the 90th-94th percentile for age, sex, and height
Stage 1 Hypertension: ≥ 95th percentile up to < 95th percentile + 12 mmHg (or 130/80-139/89 mmHg)
Stage 2 Hypertension: ≥ 95th percentile + 12 mmHg (or ≥ 140/90 mmHg)

Key Conceptual Points

The risk of cardiovascular and renal morbidity is continuous from BP levels as low as 115/75 mmHg - any definition of hypertension is, to some degree, arbitrary
Every 20 mmHg rise in SBP (or 10 mmHg in DBP) doubles the risk of death from heart disease or stroke across ages 40-89 years
The theoretical minimum risk SBP identified by the Global Burden of Disease study is 110-115 mmHg
Comprehensive Clinical Nephrology, 7th Edition, p. 487

Drugs classification

Asking for Preferences

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the information needed for a comprehensive, well-organized answer. Let me compile it.

Classification of Antihypertensive Drugs

There are five major first-line classes plus several second-line/adjunct classes. They are grouped by mechanism of action.

I. DIURETICS

Work primarily by reducing kidney sodium reabsorption, decreasing plasma volume and cardiac output. Considered "best in class" for first-step CVD prevention in meta-analyses.

A. Thiazide and Thiazide-like Diuretics (First-line)

Mechanism: Inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the distal convoluted tubule
Examples: Hydrochlorothiazide (HCTZ), Chlorthalidone, Indapamide
Note: Chlorthalidone is preferred over HCTZ (half-life 48-72h vs 16-24h - better 24h BP control)
Side effects: Hypokalemia, hyponatremia, hypomagnesemia, hyperuricemia, dyslipidemia, impaired glucose tolerance, photosensitivity
Compelling indications: Heart failure, high CAD risk, diabetes, stroke, isolated systolic hypertension

B. Loop Diuretics

Mechanism: Inhibit Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle
Examples: Furosemide, Bumetanide, Torsemide
Use: Preferred in CKD with poor GFR (where thiazides are less effective), heart failure with fluid overload
Side effects: Hypokalemia (fewer other metabolic effects than thiazides)

C. Potassium-Sparing Diuretics

Mechanism: Inhibit the epithelial sodium channel (ENaC) in the distal tubule
Examples: Amiloride, Triamterene
Use: Often combined with thiazides to prevent hypokalemia
Side effects: Hyperkalemia

II. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) BLOCKERS

A. ACE Inhibitors (ACEi) (First-line)

Mechanism: Block conversion of angiotensin I → angiotensin II by inhibiting ACE
Examples: Lisinopril, Enalapril, Ramipril, Captopril, Perindopril
Side effects: Dry cough (most common - class effect), hyperkalemia, elevated creatinine, angioedema (rare but serious), fetal toxicity (contraindicated in pregnancy)
Compelling indications: Heart failure, post-MI, high CAD risk, diabetes, CKD with proteinuria, previous stroke, LVH, microalbuminuria

B. Angiotensin Receptor Blockers (ARBs) (First-line)

Mechanism: Block binding of angiotensin II to the AT₁ receptor
Examples: Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan
Side effects: Similar to ACEi but no cough - use when ACEi cough is intolerable
Note: ACEi + ARB combination is NOT recommended (increases risk of hyperkalemia and AKI without added benefit)
Compelling indications: Same as ACEi; preferred in CKD with proteinuria and diabetes

C. Direct Renin Inhibitor (DRI)

Mechanism: Blocks conversion of angiotensinogen → angiotensin I (acts at the very start of the RAAS cascade)
Examples: Aliskiren
Side effects: Similar to ARBs; diarrhea at high doses
Note: Not first-line; contraindicated with ACEi or ARB in diabetics

III. CALCIUM CHANNEL BLOCKERS (CCBs) (First-line)

Mechanism: Inhibit the L-type voltage-gated calcium channels, reducing calcium entry into vascular smooth muscle and cardiac cells

A. Dihydropyridines (DHP) - Vasodilators

Primarily act on vascular smooth muscle
Examples: Amlodipine, Nifedipine, Felodipine, Lercanidipine, Nicardipine
Side effects: Dependent (peripheral) edema, reflex tachycardia, flushing, gingival hyperplasia
Compelling indications: High CAD risk, diabetes, isolated systolic hypertension, Black patients, asymptomatic atherosclerosis, peripheral artery disease

B. Non-Dihydropyridines - Vasodilators + Heart Rate Control

Agent	Mechanism	Side Effects
Verapamil	Vasodilation + strong AV nodal blockade	Bradycardia, constipation (most common)
Diltiazem	Vasodilation + moderate AV nodal blockade	Bradycardia

Compelling indications: Angina, atrial fibrillation rate control
Contraindicated: With beta-blockers (risk of complete heart block), in heart failure with reduced EF

IV. BETA-BLOCKERS (BB)

Mechanism: Inhibit adrenergic (beta) receptors, reducing cardiac output and renin secretion

A. Non-Selective Beta-Blockers (β₁ + β₂ block)

Examples: Propranolol, Nadolol, Timolol, Sotalol
Side effects: More bronchospasm (avoid in asthma/COPD), peripheral vasoconstriction, blunted hypoglycemia symptoms

B. Cardioselective Beta-Blockers (β₁ selective)

Examples: Atenolol, Metoprolol, Bisoprolol, Nebivolol
Side effects: Less bronchospasm (still use with caution in reactive airway disease)

C. Combined Alpha- and Beta-Blockers

Examples: Carvedilol (β₁, β₂, α₁), Labetalol (β₁, β₂, α₁)
Use: Useful in heart failure and hypertensive urgency (IV labetalol)

General side effects (all BBs): Reduced exercise tolerance, fatigue, depression, bradycardia, sexual dysfunction, masking of hypoglycemia

Compelling indications: Heart failure (bisoprolol, carvedilol, metoprolol succinate), post-MI, angina, high CAD risk, aortic aneurysm, atrial fibrillation rate control

Note: Meta-analyses show beta-blockers are inferior to other first-line classes for stroke prevention and are not recommended as first-step therapy unless a compelling indication exists.

V. ALDOSTERONE/MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRA)

Mechanism: Block aldosterone receptor in the distal nephron, reducing sodium retention

Drug	Notes
Spironolactone	Anti-androgenic side effects: gynecomastia, irregular menses, impotence; drug of choice for resistant hypertension (PATHWAY-2 study)
Eplerenone	More selective - fewer anti-androgenic side effects; used in post-MI heart failure

Compelling indications: Heart failure, post-MI, primary aldosteronism, resistant hypertension
Side effects: Hyperkalemia (monitor K⁺ and renal function)

VI. SECOND-LINE / ADJUNCT CLASSES

A. Alpha-1 Blockers

Mechanism: Block postsynaptic α₁ adrenergic receptors → vasodilation
Examples: Doxazosin, Prazosin, Terazosin
Use: Add-on for resistant hypertension; also useful in men with BPH
Caution: ALLHAT trial showed inferior CV outcomes (especially increased heart failure risk) vs. first-line agents - not used as initial therapy

B. Direct Vasodilators

Drug	Notes
Hydralazine	Arteriolar vasodilator; requires 3-4 doses/day; useful in Black patients with heart failure (+ isosorbide dinitrate)
Minoxidil	Very potent; causes significant fluid retention (must combine with loop diuretic); causes facial hirsutism; risk of pericardial effusion

C. Centrally Acting Sympatholytics (Central Alpha-2 Agonists)

Drug	Notes
Clonidine	Reduces sympathetic outflow from CNS; short-acting (2-3x/day); causes dry mouth, lethargy; rebound hypertension if stopped abruptly; transdermal patch preferred
Methyldopa	Drug of choice in pregnancy; causes sedation, hepatotoxicity
Guanfacine	Better tolerated; once-daily extended-release available; useful in dialysis patients
Moxonidine	Selective I₁ imidazoline receptor agonist; used in metabolic syndrome

VII. SPECIAL SITUATIONS - PREFERRED AGENTS

Condition	Preferred Drug(s)
Diabetes mellitus	ACEi or ARB (especially with proteinuria), CCB, thiazide
CKD with proteinuria	ACEi or ARB
Heart failure (HFrEF)	ACEi/ARB, BB (bisoprolol/carvedilol/metoprolol), MRA, diuretics
Post-MI	ACEi/ARB, BB
Angina	BB, CCB
Atrial fibrillation (rate control)	BB, non-DHP CCB (verapamil/diltiazem)
Left ventricular hypertrophy	ACEi, ARB, CCB
Isolated systolic hypertension (elderly)	Thiazide diuretic, CCB
Black patients	CCB, thiazide diuretic (ACEi/ARBs less effective as monotherapy)
Pregnancy	BB (labetalol), CCB (nifedipine), methyldopa - avoid ACEi/ARBs
Primary aldosteronism	Spironolactone/Eplerenone
Aortic aneurysm/dissection	Beta-blocker
Resistant hypertension	Add spironolactone (best evidence), then doxazosin or minoxidil

Summary Table

Class	Examples	Key Mechanism	Key Side Effects
Thiazide diuretics	Chlorthalidone, HCTZ	NCC inhibition (DCT)	Hypokalemia, hyperuricemia
Loop diuretics	Furosemide	NKCC2 inhibition	Hypokalemia
K-sparing diuretics	Amiloride	ENaC inhibition	Hyperkalemia
ACE inhibitors	Lisinopril, Ramipril	Block Ang I→II conversion	Cough, angioedema
ARBs	Losartan, Valsartan	Block AT₁ receptor	No cough (vs ACEi)
Direct renin inhibitor	Aliskiren	Block renin	Diarrhea
DHP-CCBs	Amlodipine	L-type Ca²⁺ channel block	Peripheral edema
Non-DHP-CCBs	Verapamil, Diltiazem	Ca²⁺ block + AV node	Bradycardia
Beta-blockers	Metoprolol, Carvedilol	Block β-adrenoceptors	Fatigue, bronchospasm
MRAs	Spironolactone	Aldosterone block	Gynecomastia, hyperK
Alpha-blockers	Doxazosin	Block α₁ receptors	First-dose hypotension
Direct vasodilators	Hydralazine, Minoxidil	Arteriolar dilation	Reflex tachycardia
Central alpha-2 agonists	Clonidine, Methyldopa	Reduce CNS sympathetic output	Sedation, rebound HTN

Sources: Harrison's Principles of Internal Medicine 22E (2025), p. 1942-1950 | NKF Primer on Kidney Diseases 8e, p. 691-693 | Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1413-1421

This is a shared conversation. Sign in to Orris to start your own chat.